- Home
- Test Categories
- Allergy Testing
- Autoimmune Diseases
- Blood and Blood Diseases
- Cancer Detection
- Diabetes
- DNA, Paternity and Genetic Testing
- Drug Screening
- Environmental Toxin Testing
- Female Specific Tests
- Fitness, Nutrition and Anti-Aging
- Gastrointestinal Diseases
- General Wellness
- Heart Health and Cholesterol
- Hormones and Metabolism
- Immunization Check
- Infectious Diseases
- Infertility Testing
- Kidney Diseases
- Liver Diseases
- Male Specific Tests
- Musculoskeletal Diseases
- Sexually Transmitted Diseases (STD's)
- Therapeutic Drug Monitoring
- Thyroid Diseases
- - STD Testing
- About STD Testing
- Chlamydia and Gonorrhea Test
- Cytomegalovirus (CMV) Antibodies, IgG
- Cytomegalovirus (CMV) Antibodies, IgM, Quantitative
- Epididymitis Screen
- Hepatitis A and B Immune Status Profile Test
- Hepatitis A and B Profile, Acute Diagnostic
- Hepatitis A and B Profile, Comprehensive
- Hepatitis A Antibody, IgM
- Hepatitis A Antibody, Total
- Hepatitis A Profile, Acute verses Chronic Differentiation
- Hepatitis B and C Profile Test (Comprehensive)
- Hepatitis B Core Antibody, IgG, IgM, Differentiation
- Hepatitis B Core Antibody, IgM
- Hepatitis B Core Antibody, Total
- Hepatitis B Patient Management Profile Test
- Hepatitis B Profile
- Hepatitis B Surface Antibody Test
- Hepatitis C Antibody Test
- Hepatitis C Virus (HCV), RNA PCR, Qualitative
- Hepatitis Panel, Acute
- Hepatitis Profile II (Diagnostic Follow-up)
- Herpes Simplex Virus (HSV) Type I and II IgG
- Herpes Simplex Virus (HSV) Type II IgG
- Herpes Simplex Virus (HSV), Type I and II IgM
- HIV-1 and HIV-2 Screen
- HIV-1 Antibodies Test
- HIV-1 DNA RT- PCR With HIV Antibodies , ICMA
- HIV-2 Antibodies
- Human Immunodeficiency Virus 1 (HIV-1) RNA (bDNA)
- Human Immunodeficiency Virus 2 (HIV-2), Qualitative, PCR
- Mycoplasma/Ureaplasma, Real-Time PCR
- Soluble Liver Antigen (SLA) IgG Antibody (Autoimmune Hepatitis)
- STD Recent Exposure Panel
- STD Urinary Tract Infection Panel
- Syphilis (RPR) Test
- Treponema pallidum Antibodies (TP-PA)
- Ultimate STD Panel
- Ultimate Viral STD Panel
- See All STD Tests
- - Blood Tests
- Allergy Testing
- Autoimmune Disease Testing
- Blood Disorder and Blood Disease Testing
- Cancer Detection Testing
- Diabetes Testing
- DNA, Paternity and Genetic Testing
- Drug Screening Testing
- Environmental Testing
- Female-Specific Testing
- Fitness, Nutrition and Anti-Aging Testing
- Gastrointestinal Disease Testing
- General Wellness Testing
- Heart Health and Cholesterol Testing
- Hormone Blood Tests
- Immunization Testing
- Infectious Disease Testing
- Infertility Testing
- Kidney Disease Testing
- Liver Function Tests
- Musculoskeletal Disorders Testing
- Prostate Testing
- Therapeutic Drug Monitoring Testing
- Thyroid Testing
- - All Tests
- Lab Locations
- Wishlist New!
- Why Online Lab Tests
- How it Works
- About Us
- FAQ
- Health Resources
Questions?
1.877.283.7882
1.877.283.7882
Private MD News
Home | News | OvarianOvarian cancer researchers testing new drug
Updated: 2009-09-09 22:11:02 CST Category: Ovarian
by Brendan Missett
Coincident with Ovarian Cancer Awareness Month, the National Cancer Institute is beginning to test a new drug it hopes will more effectively treat types of breast and ovarian cancer.
Dr. Elise Kohn of the Center for Cancer Research will head a clinical trial which tests the effectiveness of the drug AZD2281 in thwarting the repair of mutated genes. The trial is in phase I, which means that safety of the treatment will be the main factor examined.
Prior research has shown that women who have mutations to their BRCA, or tumor suppressor genes, are at a much higher risk of developing breast or ovarian cancer. In the new trial, researchers will administer the new drug and hope that it stunts the capacity of damaged cancer cells to repair themselves.
Kohn summarized the trial stating, "The idea is to stress the cancer cells with [chemotherapy], which is known to be effective in ovarian cancer and possibly some breast cancers, while blocking DNA repair pathways."
Tests on animals have demonstrated that the AZD2281 drug is significantly more toxic to cells with BRCA gene mutations than to cells with normal tumor suppressor genes.
The NCI reports that ovarian cancer testing can help find cancer at an early stage and increase the likelihood that it can be successfully treated.
Related Articles from Private MD:
-
Ovarian cancer testing leads to new treatment technique
-
Doctor: Women should get tested to catch ovarian cancer early
-
Representative urges women to get frequent cancer tests
-
Early screening key for ovarian cancer
Subscribe to Private MD Health News RSS Feed: 
News Categories:
Advanced Lipid Treatment I Allergy Testing Anemia and RBC disorders Autoimmune Diseases Bariatric Lab Testing Blood and Blood Diseases Breast Cancer Detection and Tumor Markers Celiac Disease Testing Chlamydia Coagulation and blood clotting disorders Colon Diabetes DNA, Paternity and Genetic testing Drug Screening Environmental Toxin Testing Female Specific Tests Gastrointestinal Diseases General Health General Wellness Heart Health and Cholesterol Herpes HIV HIV monitoring/Treatment/Testing/Post Diagnos Hormones and Metabolism Infectious Diseases Infertility Testing-Male Infertitlity Hormone Testing Kidney Diseases Leukemia and WBC disorders Liver Liver Diseases Lyme Disease Male Specific Tests Menopause/Peri-Menopausal Diagnosis Organ Specific Testing Ovarian Prostate Sexually Transmitted Diseases Thyroid Diseases Vitamin D Deficiency-Diagnosis and Treatment
Visit the Health News Archive: Click Here
Questions about online blood testing or how to order a lab test? Click here to get started or call us toll-free at 1.877.283.7882. Our certified professionals are ready to assist you.
